On November 20, 2018 Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development and commercialization of innovative therapeutics for the treatment of cancer, reported three upcoming poster presentations at the 60th annual meeting of the American Society of Hematology (ASH) (Free ASH Whitepaper) (Press release, Curis, NOV 20, 2018, View Source [SID1234531504]). Curis’s poster presentations will be available for viewing on Monday, December 3 (Session III) from 10 a.m. to 8 p.m. PT with presentations from 6 p.m. to 8 p.m. PT in Hall GH at the San Diego Convention Center.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Curis will present three posters at the ASH (Free ASH Whitepaper) conference providing key information supporting development of fimepinostat in patients with DLBCL, including patients with MYC-alterations, and CA-4948, Curis’s IRAK4 inhibitor, for patients with lymphomas. A pooled analysis of R/R DLBCL patients treated with fimepinostat demonstrates adequate safety and anti-tumor activity supporting the biologic rationale for continued development of fimepinostat in this patient population. Additionally, Curis will present preclinical data and biological rationale that support CA-4948 development in patients with tumors sensitive to the IRAK4 signaling pathway as well as data supporting the potential for IRAK4-based combination regimens to overcome drug tolerance in patients with Non-Hodgkin Lymphoma.

Details of these presentations are as follows:

Curis Presentations at American Society of Hematology (ASH) (Free ASH Whitepaper) 60th Annual Meeting

Viewing Date/Time:

Monday, Dec. 3, 10:00 AM – 8:00 PM PT

Presentation Date/Time:

Monday, Dec. 3, 6:00 PM – 8:00 PM PT

Location:

Hall GH, San Diego Convention Center

Abstract Number:

4168

Presentation Title:

Preclinical Activity of IRAK4 Kinase Inhibitor CA-4948 Alone or in Combination with Targeted Therapies and Preliminary Phase 1 Clinical Results in Non-Hodgkin Lymphoma

Abstract Number:

4184

Presentation Title:

A Pooled Analysis of Relapsed/Refractory Diffuse Large B-Cell Lymphoma Patients Treated with the Dual PI3K and HDAC Inhibitor Fimepinostat (CUDC-907), Including Patients with MYC-Altered Disease

Abstract Number:

2649

Presentation Title:

Drug Combinations Co-Targeting Myeloid Cell Leukemia-1 (Mcl-1) Protein Can Overcome Microenvironmentally-Induced Multi-Drug Tolerance in Non-Hodgkin Lymphomas